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Dear editor
In a recent article, Yolande Lucire and Christopher Crotty presented their findings in an 
ongoing naturalistic study concerning a possible relationship between variant alleles in 
three CYP450 genes and a variety of behavioral problems.1 Unfortunately, the tested 
population of 129 persons was very heterogeneous and poorly characterized from a phe-
nomenological perspective. In the results section of their article, the authors use the term 
“akathisia” to describe the adversity, but without defining this phenomenon. They also use 
this term in the title of their paper. Since they state that the majority of the persons who 
experienced adverse clinical events had akathisia, which is not expected considering their 
clinical characteristics, it is possible that the term has been used to describe other types of 
problems rather than this well-defined extrapyramidal motor disorder.2,3 In our opinion, 
this is unfortunate as it may lead to false interpretation of the mechanistic background of 
these putative side effects. As a matter of fact, such a false interpretation of the relationship 
between aggression and akathisia has probably led to misunderstandings during a number 
of court trials in the Netherlands. On one occasion, an accused person was sentenced to 24 
years in prison because of an erroneous interpretation of the message of Lucire and Crotty’s 
paper.4 Because the motor symptoms of akathisia were not confirmed by a small number 
of layman observers prior to his committing the felony, the judges rejected akathisia as a 
possible explanation for this aggressive behavior. It is important, therefore, not to use the 
term “akathisia” as being synonymous with drug-induced aggression. There are many 
other possible mechanisms which could cause selective serotonin reuptake inhibitors to 
lead to this type of adversity5 and, in addition, it should be noted that adverse clinical 
events are only very rarely monocausally related to the intake of a drug.
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Dear editor
Lucire and Crotty1 correlated the extrapyramidal side effect 
called akathisia with aggression, suicide, and homicide 
starting in the 1950s. Akathisia ranges in intensity from mild 
discomfort to the most painful and dangerous mental state 
known to psychiatry. Research from the pharmaceutical 
industry has also correlated antidepressants with akathisia 
suicide and diminished activity at CYPP450.2
Along with intense dysphoria, the subjects, few of 
whom had a prior history of mental illness, suicidality or 
aggression, experienced variable and shifting combinations 
of neurotoxic phenomena: thoughts of death and dying, 
uncharacteristic aggression, suicidality, impulsivity, insom-
nia, paroniria, restless pacing (sometimes only at night), 
driving long distances in a dissociated state, exercising 
excessively to work off energy, worsening depression and/
or manic shift along with behavioral dyscontrol. Each drug’s 
product information lists some of the myriad manifestations 
of neurotoxicity which are also documented in the Inter-
national Classification of Diseases (F10–F19: Mental and 
behavioral disorders due to psychoactive substance use), 
in Diagnostic and Statistical Manual of Mental Disorders 
(DSM)-IV and in DSM-5 as a dozen substance/medication-
induced disorders listed alongside the mental illnesses they 
suggest or mimic. Being side effects or intoxications and 
not mental illnesses, they have no numerical codes. DSM-
III defined akathisia as a subjective desire to be in constant 
motion caused by drug sensitivity.
Inquiry must be made about how the subjects feels 
outside of the interview room, as this movement disorder 
fluctuates and is often missed, only treacherously to return an 
hour or a day later.3,4 Reports of subjective or objective rest-
lessness are strongly associated with aggression, violence, 
and suicide and can forewarn of a psychiatric emergency. Of 
the subjects tested in Lucire and Crotty, a handful could not 
sit still during the consultation and episodes of restlessness 
were many times more frequently reported than observed. 
The subject’s mental state had more predictive value than 
observed movements defined by the Barnes Akathisia 
Scale.5 According to DSM-IV, the condition fluctuates and 
the subjects described bouts of restless legs, twitching, toe 
turning, pacing, and other activities occurring outside of 
the interview hours.
In clinical trials presented to the United States Food and 
Drug Administration for each drug’s licensing, akathisia rates 
were underestimated because the condition was recorded 
only when its physical manifestations appeared in front of 
the interviewer. Because of this systemic error, resulting in 
the underdiagnosis of this condition, suicides occurred on 
active substance and in withdrawal in most clinical trials for 
antidepressants. 
Professor Loonen’s notion that identification of akathisia 
should be limited to what has been observed within a very 
circumscribed timeframe would result in even more cases 
being missed, with tragic consequences.6 
The person to whom Professor Loonen refers to was 
prescribed paroxetine (Inh 1A2, Inh 2C9, Inh 2C19, Sub 
Inh 2D6, Inh 3A4) for marriage difficulties, and he took it 
irregularly.7 On the day in question, he took 40 mg and, for his 
asthma, he inhaled an unknown quantity of budesonide (Sub 
3A4) and formoterol (2A6, Sub 2C8, Sub 2C19, Sub 2D6) 
while he drank his habitual dozen beers. Alcohol inhibits 
CYP2B6, CYP2C9, CYP2C19, and CYP3A4.
He then suffered a psychological blow and, by his account, 
his “lights went out” and he suddenly became violent, fetched 
an antique gun, smashed a window, shot and  injured two 
people, then he drove further and killed another person and 
continued to drive for several more hours while feeling both 
hot and cold and shaking violently. The court rejected evidence 
on the basis that akathisia was not observed before he devel-
oped it quite suddenly when he experienced a psychological 
blow. The sequence of events was poorly understood by the 
court. The homicidal behavior was concurrent with symptoms 
of serotonin toxicity which is associated with akathisia and 
manifested in his restless driving and aggression which were 
followed by patchy amnesia. 
The only way that akathisia can be diagnosed after an 
event is by asking the patient about his mental state, experi-
ence, and behavior at the time of the homicide. 
The appeal was not lost because of a judicial misinterpreta-
tion of Lucire and Crotty, but because Professors Loonen and 
Verkes were apparently unaware of the literature describing 
acute episodes of violence caused by an interaction between 
alcohol and selective serotonin reuptake inhibitors (SSRIs), 
so they attributed his homicidal behavior to alcohol, while 
telling the court that akathisia had not been observed by 
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others who saw him before it developed. Alcohol interferes, 
perhaps by competing, perhaps pharmacogenetically, with the 
metabolism of the SSRI, or the SSRI interferes with alcohol 
metabolism sometimes producing pathological intoxication 
and sometimes concurrent violence. Case reports show blood 
levels of alcohol to be much higher than expected from the 
volume consumed. Our opinion was that this man’s habitual 
consumption of alcohol, together with a starting dose of 40 
mg of paroxetine (with side effects which include impulsiv-
ity, akathisia, restlessness, and aggression) together with a 
psychological blow precipitated this episode of homicidal 
akathisia.8 
Akathisia is rarely monocausal in clinical practice. It is 
dose related and cases formerly thought to be idiosyncratic 
are now known to be associated with diminished cytochrome 
metabolism, the co-prescription of cytochrome inhibitors, 
the removal of inducers, competition from polypharmacy 
for enzymatic substrate, diet and age of the patient, and their 
general and liver health.
Disclosure
The author reports no conflicts of interest in this 
communication.
References
1. Lucire Y, Crotty C. Antidepressant-induced akathisia-related homicides 
associated with diminishing mutations in metabolizing genes of the 
CYP450 family. Pharmgenomics Pers Med. 2011;4:65–81.
2. Lane RM. SSRI-induced extrapyramidal side-effects and akathisia: 
implications for treatment. J Psychopharmacol. 1998;12(2):192–214.
3. Weiden PJ, Mann JJ, Haas G, Mattson M, Frances A. Clinical nonrecog-
nition of neuroleptic-induced movement disorders: a cautionary study. 
Am J Psychiatry. 1987;144(9):1148–1153.
4. Akagi H, Kumar TM. Lesson of the week: Akathisia: overlooked at a 
cost. BMJ. 2002;324(7352):1506–1507. 
5. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 
1989;154:672–676.
6. Hirose S. The causes of underdiagnosing akathisia. Schizophr Bull. 
2003;29(3):547–558. 
7. Eikelenboom-Schieveld SJ, Lucire Y, Fogleman JC. The relevance of 
cytochrome P450 polymorphism in forensic medicine and akathisia-related 
violence and suicide. J Forensic Leg Med. 2016;41:65–71. 
8. Herxheimer A, Menkes DB. Drinking alcohol during antidepressant treat-
ment–a cause for concern? The Pharmaceutical Journal. 2011;287:732. 
Dove Medical Press encourages responsible, free and frank academic debate. The content of the Pharmacogenomics and Personalized Medicine ‘letters to the editor’ section does not necessarily 
represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Pharmacogenomics and Personalized Medicine editors. While all reasonable steps have been 
taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.
 
Ph
ar
m
ac
og
en
om
ics
 a
nd
 P
er
so
na
liz
ed
 M
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
1.
17
4.
24
8.
14
9 
on
 1
4-
Fe
b-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
